Evidence map›Paper›PMID 39751933›Full record

ArticleCalcified tissue international2025

The Delicate Balancing of Pros and Cons in the Surgical Management of Hyperparathyroidism in a Young Female with Germline Variant in the CDC73 Gene.

Lotte Steyaert, Karel David, Jeroen Breckpot, Marleen Renard, Vincent Vander Poorten, Brigitte Decallonne

Abstract readCase Reports
In one paragraph

Article in Calcified tissue international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Lotte SteyaertDepartment of Endocrinology, University Hospitals Leuven, Herestraat 49, 3000, Leuven, Belgium.
Karel DavidDepartment of Endocrinology, University Hospitals Leuven, Herestraat 49, 3000, Leuven, Belgium.
Jeroen BreckpotCenter for Human Genetics, University Hospitals Leuven, Leuven, Belgium.
Marleen RenardDepartment of Pediatrics, University Hospitals Leuven, Leuven, Belgium.
Vincent Vander PoortenDepartment of Otorhinolaryngology, Head and Neck Surgery, University Hospitals Leuven, Leuven, Belgium.
Brigitte DecallonneDepartment of Endocrinology, University Hospitals Leuven, Herestraat 49, 3000, Leuven, Belgium. brigitte.decallonne@uzleuven.be.ORCID 0000-0003-4153-4757

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hyperparathyroidism-jaw tumor syndrome is a rare form of syndromic primary hyperparathyroidism. We describe a young female with a history of common precursor B acute lymphoblastic leukaemia who was diagnosed with overt primary hyperparathyroidism due to a pathogenic CDC73 variant (c.25C > T). This patient posed several challenging management aspects: the development of nephrocalcinosis, the risk for parathyroid carcinoma, and persistent hyperparathyroidism after two selective parathyroidectomies, leading to the decision to perform a total parathyroidectomy. The latter resulted in permanent complete hypoparathyroidism, with subsequent difficult medical therapy. This case report illustrates the challenge to identify the optimal treatment of parathyroid disease in the context of hyperparathyroidism-jaw tumor syndrome, balancing the risks of hyperparathyroidism and parathyroid carcinoma against the burden of permanent hypoparathyroidism at young age.

Indexed as

HyperparathyroidismParathyroidectomyTumor Suppressor ProteinsAdultFemaleGerm-Line MutationHumansHyperparathyroidism, PrimaryParathyroid NeoplasmsCDC73 protein, humanTumor Suppressor ProteinsCDC73HPT-JT syndromeParathyroid carcinomaParathyroidectomyPrimary hyperparathyroidism

Identifiers

PMID39751933
PMCPMC11698747

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.